



Editorial Comment: The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis

Correa RJM¹, Louie AV², Zaorsky NG³, Lehrer EJ⁴, Ellis R⁵, Ponsky L⁵, et al.

¹ Department of Radiation Oncology, London Regional Cancer Program, London, Ontario, Canada; ² Department of Radiation Oncology, Sunnybrook Health Sciences Centre and the University of Toronto, Toronto, Ontario, Canada; ³ Department of Radiation Oncology, Penn State Cancer Institute, Hershey, PA, USA; ⁴ Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; ⁵ University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, OH, USA

Eur Urol Focus. 2019 Nov;5(6):958-969

DOI: 10.1016/j.euf.2019.06.002 | ACCESS: [10.1016/j.euf.2019.06.002](https://doi.org/10.1016/j.euf.2019.06.002)

Stênio de C. Zequi¹

¹ A. C. Camargo Cancer Center, Fundação Prudente, São Paulo, SP, Brasil

COMMENT

Historically, urologists do not recommend external beam radiotherapy for patients with renal cell carcinoma. But the progresses of radiotherapy have permitted the use of a high-precision stereotactic ablative radiotherapy in hypofractionated scheduling. It seems a therapeutic alternative of for elderly and frail patients which are not surgical candidates. The rational is to offer a single session of 26Gy or a short course of 40Gy, delivered only on five sessions, in an outpatient treatment. The endpoints must be tumor size reduction or no tumoral progression, being interesting for symptomatic candidates. The results are acceptable and side effects are tolerable. In face recent reports in the literature, Correa and several international key opinion leaders, published this metanalysis, that evaluated 26 selected studies. Reading this article, we can ourselves updated on this therapeutic approach, destined for a subgroup of patients that usually has almost none options of treatment.

Stênio de C. Zequi, MD

A. C. Camargo Cancer Center, Fundação Prudente,
São Paulo, SP, Brasil
E-mail: steniozequi@gmail.com

ARTICLE INFO

 **Stenio C Zequi**
<https://orcid.org/0000-0003-1897-8085>

Int Braz J Urol. 2020; 46: 473-3